Children as young as two with either sickle cell disease or thalassemia are now eligible for the gene therapy.

The industry looks set to continue a preference for European outsourcing facilities as national tax systems exert influence.

Our editorial team delve into the key takeaways from the 2026 HLTH Europe conference and the 2026 BIO International Convention.

Ipsen’s Memo acquisition is the second the former has signed this week alone, following its blockbuster Kartos buyout on 29 June.

Inocras has entered a strategic partnership with AimedBio to enhance cancer drug development using whole genome intelligence.

In Sanofi's Baby-COMET trial, Nexviazyme met all primary and secondary endpoints, teeing it up for potential label expansion in Pompe disease.

Bocunebart's PACAP-targeting mechanism positions it as a potential first-in-class therapy in a thin pipeline of novel late-stage candidates ...

Anthropic launches Claude Science as big tech companies increasingly eye expansion in the wider healthcare and life sciences space.

Eli Lilly’s retatrutide has crossed the 30% weight loss benchmark in some patients. Where do GLP-1RAs go from here?

Eli Lilly and Company has entered into an agreement with Innovent Biologics for the commercialisation of Verzenios in mainland China.

The number of RMAT designations awarded by the FDA increased sharply from 2024, reaching a record of 48 RMAT designations in 2025.

The US FDA has declined to approve Unicycive Therapeutics’ resubmitted NDA for OLC to treat hyperphosphatemia in CKD patients on dialysis.